Bell et al., 2016 - Google Patents
In‐depth characterization of the salivary adenoid cystic carcinoma transcriptome with emphasis on dominant cell typeBell et al., 2016
View PDF- Document ID
- 13409675831987046139
- Author
- Bell D
- Bell A
- Bondaruk J
- Hanna E
- Weber R
- Publication year
- Publication venue
- Cancer
External Links
Snippet
BACKGROUND Adenoid cystic carcinoma (ACC), 1 of the most common salivary gland malignancies, arises from the intercalated ducts, which are composed of inner ductal epithelial cells and outer myoepithelial cells. The objective of this study was to determine the …
- 201000007416 salivary gland adenoid cystic carcinoma 0 title abstract description 102
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bell et al. | In‐depth characterization of the salivary adenoid cystic carcinoma transcriptome with emphasis on dominant cell type | |
Dong et al. | Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer | |
Guler et al. | Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA | |
Dijk et al. | Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems | |
Nie et al. | Long non‐coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival | |
Lu et al. | Common human cancer genes discovered by integrated gene-expression analysis | |
Lu et al. | Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles | |
Cecco et al. | Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2 | |
Yang et al. | Low expression of chloride channel accessory 1 predicts a poor prognosis in colorectal cancer | |
Pan et al. | Identifying a confused cell identity for esophageal squamous cell carcinoma | |
Macagno et al. | Wholistic approach: transcriptomic analysis and beyond using archival material for molecular diagnosis | |
Shariat et al. | p53 expression in patients with advanced urothelial cancer of the urinary bladder | |
Hashmi et al. | Molecular subtypes of breast cancer in South Asian population by immunohistochemical profile and Her2neu gene amplification by FISH technique: association with other clinicopathologic parameters | |
Bismar et al. | Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10‐gene signature with relevant implication to patients' clinical outcome | |
YuFeng et al. | Expression and prognostic roles of PABPC1 in hepatocellular carcinoma | |
Gorlick et al. | HER‐2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study | |
Gazquez et al. | Biomarkers vs conventional histological analysis to detect lymph node micrometastases in bladder cancer: a real improvement? | |
Xiao et al. | Non‐invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study | |
Farid et al. | Expression of CD133 and CD24 and their different phenotypes in urinary bladder carcinoma | |
Jandova et al. | Sporadic early-onset colon cancer expresses unique molecular features | |
Zhou et al. | High vimentin expression with E-cadherin expression loss predicts a poor prognosis after resection of grade 1 and 2 pancreatic neuroendocrine tumors | |
Joung et al. | Significance of intratumoral fibrosis in clear cell renal cell carcinoma | |
Na et al. | High expression of Aldolase A predicts poor survival in patients with clear-cell renal cell carcinoma | |
Hu et al. | Overexpression of suppressor of zest 12 is associated with cervical node metastasis and unfavorable prognosis in tongue squamous cell carcinoma | |
Guo et al. | Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis |